|
- Soleno Therapeutics – Development and commercialization of novel . . .
Soleno is committed to maximizing shareholder value by developing and commercializing innovative therapeutic products with the goal of improving the lives of individuals living with complex, life-threatening rare diseases with unmet medical needs
- Products - Soleno
Trench Drain Trench Drain for residential, commercial and industrial use Triple Wall Pipe TripleFlo is the triple-wall pipe offered exclusively by Soleno Rigid pipe with smooth interior and exterior walls for drainage applications Composed of three interconnected layers of HDPE, it is designed to offer an exceptional level of rigidity
- Connecting you to the future of water management - Soleno USA
Subscribe to our newsletter Stay tuned for our latest innovations, technical documents and news Subscribe case-studies SUSTAINABILITY APPLICATIONS PRODUCTS TECHNOLOGY RESOURCES CENTER TERMS AND CONDITIONS Learn More ABOUT US CAREERS CONTACT US MEMBERSHIPS LUNCH AND LEARN Privacy Policy © SOLENO LLC
- Could Soleno Therapeutics Have Room to Run After FDA Designation Sparks . . .
Curious whether Soleno Therapeutics is a hidden gem or already overhyped? You're not alone, and now is the perfect time to take a closer look at what the numbers suggest about its value The stock
- Soleno opens first U. S. plant - Geosynthetics Magazine
Soleno, a Quebec leader in water management, announces the opening of its first plant in the United States, in Saratoga Springs, N Y , confirming the company’s momentum and its determination to offer sustainable solutions to counter the aging of water management infrastructure in North America
- First Developer of Solutions for Mastering Water Sustainably - Soleno
Soleno is your partner for the agriculture of tomorrow By delivering innovative water management solutions, we can optimize water usage and quality for better biodiversity, soil sustainability and crop efficiency
- A Look at Soleno Therapeutics (SLNO) Valuation Following $100 Million . . .
Soleno Therapeutics (SLNO) has just announced a $100 million accelerated share repurchase agreement with Jefferies LLC The company aims to buy back a sizable chunk of its common stock over the coming months This move highlights management’s confidence in the company’s long-term outlook See our latest analysis for Soleno Therapeutics Soleno Therapeutics’ announcement comes after a
- Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing . . .
SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov 7, 2025 PRNewswire -- On November 5, 2025, investors in Soleno Therapeutics, Inc (NASDAQ: SLNO) saw the price of their shares tumble $18 78 (-28%) after the company reported disappointing information about VYKAT™ XR, a once-daily oral tablet intended to treat hyperphagia Soleno has described this
|
|
|